Janssen-cilag G.m.b.h

This study follows 400 people with Crohn's disease or ulcerative colitis who are starting guselkumab, a biologic treatment. Researchers will measure how many achieve remission and how the drug affects symptoms like fatigue, quality of life, and work productivity. The goal is to u…